Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.
10.1007/s13238-017-0412-8
- Author:
Shuguang TAN
1
;
Kefang LIU
2
;
Yan CHAI
1
;
Catherine W-H ZHANG
3
;
Shan GAO
4
;
George F GAO
1
;
Jianxun QI
5
Author Information
1. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.
2. National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, 102206, China.
3. ImmuFuCell Biotechnology Co.Ltd., Beijing, 100102, China.
4. CAS Key Laboratory of Bio-medical Diagnostic, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, 215163, China.
5. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China. jxqi@im.ac.cn.
- Publication Type:Letter
- MeSH:
Antibodies, Monoclonal;
chemistry;
metabolism;
therapeutic use;
B7-H1 Antigen;
chemistry;
metabolism;
Humans;
Kinetics;
Models, Molecular;
Protein Binding
- From:
Protein & Cell
2018;9(1):135-139
- CountryChina
- Language:English
